About: Intercell

An Entity of Type: Aktiengesellschaft, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.It employs 400 people in Austria, Scotland and the United States. It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based , a developer of needle-free vaccination technology.

Property Value
dbo:abstract
  • Die Intercell AG war ein österreichisches Biotechnologieunternehmen mit Sitz in Wien, das auf die Entwicklung von prophylaktischen und therapeutischen Impfstoffen gegen Infektionskrankheiten spezialisiert war. Intercell kooperierte mit den Pharmaunternehmen Novartis, MSD oder Sanofi-Aventis. Am 28. Mai 2013 vereinigte sich das Unternehmen mit der französischen Vivalis SA zu einer Firma mit dem Unternehmensnamen Valneva SE. (de)
  • Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.It employs 400 people in Austria, Scotland and the United States. It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based , a developer of needle-free vaccination technology. Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production. The most important projects of Intercell are: * Vaccine against Japanese encephalitis (approved in Europe, America and Australia) * Therapeutic vaccine against hepatitis C (in clinical phase II) * Antigen identification program and adjuvant technologies. * Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II) (en)
  • Intercell est une entreprise autrichienne ayant fait partie de l'indice ATX. En mai 2013, elle a fusionné avec l'entreprise française Vivalis SA pour former Valneva SE. (fr)
dbo:assets
  • 2.252E8
dbo:equity
  • 1.211E8
dbo:fate
  • Merged with Vivalis SA (en)
dbo:foundingYear
  • 1998-01-01 (xsd:gYear)
dbo:industry
dbo:keyPerson
dbo:netIncome
  • 2.552E8
dbo:numberOfEmployees
  • 410 (xsd:nonNegativeInteger)
dbo:operatingIncome
  • 2.512E8
dbo:product
dbo:revenue
  • 3.42E7
dbo:successor
dbo:thumbnail
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 17861621 (xsd:integer)
dbo:wikiPageLength
  • 6261 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1092501414 (xsd:integer)
dbo:wikiPageWikiLink
dbp:assets
  • 2.252E8
dbp:equity
  • 1.211E8
dbp:fate
  • Merged with Vivalis SA (en)
dbp:foundation
  • 1998 (xsd:integer)
dbp:homepage
dbp:industry
dbp:keyPeople
  • Thomas Lingelbach , Michel Gréco (en)
dbp:locationCity
dbp:locationCountry
dbp:logo
  • Intercell.svg (en)
dbp:logoSize
  • 120 (xsd:integer)
dbp:name
  • Intercell AG (en)
dbp:numEmployees
  • 410 (xsd:integer)
dbp:products
  • Development of vaccines (en)
dbp:revenue
  • 3.42E7
dbp:successor
dbp:tradedAs
  • OTCQX: INRLY (en)
  • WBAG: ICLL (en)
dbp:type
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Die Intercell AG war ein österreichisches Biotechnologieunternehmen mit Sitz in Wien, das auf die Entwicklung von prophylaktischen und therapeutischen Impfstoffen gegen Infektionskrankheiten spezialisiert war. Intercell kooperierte mit den Pharmaunternehmen Novartis, MSD oder Sanofi-Aventis. Am 28. Mai 2013 vereinigte sich das Unternehmen mit der französischen Vivalis SA zu einer Firma mit dem Unternehmensnamen Valneva SE. (de)
  • Intercell est une entreprise autrichienne ayant fait partie de l'indice ATX. En mai 2013, elle a fusionné avec l'entreprise française Vivalis SA pour former Valneva SE. (fr)
  • Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.It employs 400 people in Austria, Scotland and the United States. It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based , a developer of needle-free vaccination technology. (en)
rdfs:label
  • Intercell (de)
  • Intercell (fr)
  • Intercell (en)
owl:sameAs
skos:closeMatch
prov:wasDerivedFrom
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Intercell AG (en)
is dbo:predecessor of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License